Drug Trial Radar · NCT02792231
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
Last checked: Nov 20, 2026Latest source record: Nov 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
955
Actual
Start
Aug 26, 2016
Primary completion
Jul 10, 2019
Study completion Oct 22, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 7, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
Conditions
- Relapsing Multiple Scelrosis
Interventions
Ofatumumab subcutaneous injectionDrug
Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
Teriflunomide-matching placebo capsulesDrug
Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
Teriflunomide capsuleDrug
Teriflunomide 14 mg oral capsule taken once daily
Matching placebo of ofatumumab subcutaneous injectionsDrug
Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: Baseline up to 2.5 years
Locations
178 sites in 30 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Cullman, Alabama
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Aurora, Colorado
Novartis Investigative Site
Basalt, Colorado
Novartis Investigative Site
Boulder, Colorado
Novartis Investigative Site
Centennial, Colorado
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Fort Collins, Colorado
Novartis Investigative Site
Fort Collins, Colorado
Novartis Investigative Site
Fairfield, Connecticut
Novartis Investigative Site
Newark, Delaware
Novartis Investigative Site
Bradenton, Florida
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Maitland, Florida
Novartis Investigative Site
Ocala, Florida
Novartis Investigative Site
Oldsmar, Florida
Novartis Investigative Site
Ormond Beach, Florida
Novartis Investigative Site
Palm Coast, Florida
Novartis Investigative Site
Sarasota, Florida
Novartis Investigative Site
St. Petersburg, Florida
Novartis Investigative Site
Tallahassee, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Suwanee, Georgia
Novartis Investigative Site
Anderson, Indiana
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Wellesley, Massachusetts
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
Golden Valley, Minnesota
Novartis Investigative Site
Billings, Montana
Novartis Investigative Site
Great Falls, Montana
Novartis Investigative Site
Albuquerque, New Mexico
Novartis Investigative Site
Asheville, North Carolina
Novartis Investigative Site
Charlotte, North Carolina
Novartis Investigative Site
Greensboro, North Carolina
Novartis Investigative Site
Akron, Ohio
Novartis Investigative Site
Columbus, Ohio
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.